Brookline Capital Reiterates Buy on Adial Pharmaceuticals, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital analyst Kumaraguru Raja has reiterated a 'Buy' rating on Adial Pharmaceuticals (NASDAQ:ADIL) and maintained a $6 price target.
July 12, 2023 | 9:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adial Pharmaceuticals has received a reiterated 'Buy' rating from Brookline Capital, with a maintained price target of $6.
The reiterated 'Buy' rating and maintained price target by Brookline Capital indicates a positive outlook for Adial Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100